Keyword: Revlimid

Only days after Celgene dodged a U.S. patent attack on its megablockbuster drug Revlimid, a copycat has rolled onto the market in Europe.

Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.

BMS execs faced a tough audience during its Q4 report, as analysts pressed them for details about how the Celgene merger would drive growth.

Past pharma mergers have spawned price hikes, two U.S. representatives argue—and DTC and DOJ need to weigh the $74 billion deal with that in mind.

New cancer drugs in the BMS-Celgene pipeline won't be enough to cover an earlier-than expected Revlimid patent loss, analysts say.

BMS's buyout of Celgene values it at $102.43 a share—54% higher than its closing price on Wednesday evening.

Celgene’s Revlimid may have slipped in previously untreated follicular lymphoma. But in the second-line setting, the drug has a win.

Celgene is extracting volume-driven sales growth as the entire industry has come under scrutiny for its pricing.

Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon.